Weybosset Research & Management LLC Boosts Holdings in Illumina, Inc. (NASDAQ:ILMN)

Weybosset Research & Management LLC raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 14.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,638 shares of the life sciences company’s stock after acquiring an additional 2,586 shares during the quarter. Illumina makes up about 0.9% of Weybosset Research & Management LLC’s holdings, making the stock its 22nd largest holding. Weybosset Research & Management LLC’s holdings in Illumina were worth $2,758,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Partnership Wealth Management LLC increased its stake in Illumina by 17.0% during the fourth quarter. Partnership Wealth Management LLC now owns 8,095 shares of the life sciences company’s stock worth $1,082,000 after acquiring an additional 1,175 shares during the last quarter. Douglas Lane & Associates LLC boosted its holdings in Illumina by 1.5% in the fourth quarter. Douglas Lane & Associates LLC now owns 294,787 shares of the life sciences company’s stock valued at $39,392,000 after purchasing an additional 4,442 shares during the period. Everence Capital Management Inc. purchased a new position in Illumina in the fourth quarter worth approximately $414,000. GAMMA Investing LLC lifted its position in shares of Illumina by 6.1% during the 4th quarter. GAMMA Investing LLC now owns 3,096 shares of the life sciences company’s stock worth $414,000 after purchasing an additional 177 shares during the last quarter. Finally, Versant Capital Management Inc raised its stake in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 3.6 %

ILMN traded down $5.03 on Friday, reaching $134.65. 417,888 shares of the company traded hands, compared to its average volume of 1,230,963. The stock’s 50 day moving average price is $141.37 and its 200-day moving average price is $132.08. The company has a market cap of $21.36 billion, a price-to-earnings ratio of -13.52 and a beta of 1.11. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same period last year, the company earned $0.33 earnings per share. Illumina’s quarterly revenue was down 3.5% compared to the same quarter last year. On average, sell-side analysts expect that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on ILMN shares. Morgan Stanley reaffirmed an “equal weight” rating and set a $156.00 price objective on shares of Illumina in a report on Tuesday, November 12th. Robert W. Baird raised their target price on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Stephens upped their price objective on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a research report on Thursday, October 17th. Finally, Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective on the stock in a research report on Thursday, October 17th. Eight investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $165.95.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.